ArticleBMC cardiovascular disorders2025
Association of neutrophil-to-albumin ratio with all-cause and cardiovascular mortality in community-dwelling individuals with chronic kidney disease: evidence from the NHANES 1999-2018.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neutrophil Percentage-to-Albumin Ratio Predicts Contrast-Induced Acute Kidney Injury in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2025Article
- Machine learning-based predictive model for acute pancreatitis-associated lung injury: a retrospective analysis.Frontiers in medicine · 2025Article
- Association of Neutrophil Percentage-To-Albumin Ratio With All-Cause and Cardiovascular Mortality in Chronic Kidney Disease.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe relationship between the neutrophil percentage-to-albumin ratio (NPAR) and all-cause mortality as well as cardiovascular disease (CVD) mortality, in individuals with chronic kidney disease (CKD), remains unclear. This study aimed to elucidate the association between NPAR and mortality risks in CKD individuals.
methodsThe study analyzed a prospective cohort of CKD individuals from the National Health and Nutrition Examination Survey (NHANES) spanning the years 1999 to 2018. Cox proportional hazards regression model estimated the hazard ratios and 95% confidence intervals to assess the association between NPAR and the risk of all-cause and CVD mortality. Restricted cubic spline (RCS) analysis was conducted to investigate potential nonlinear relationships and segmented Cox proportional hazards regression models were used to evaluate threshold effects. Additionally, stratified analyses were performed to examine the relationship between NPAR and mortality across different subgroups.
resultsThe study include 3,029 community-dwelling CKD individuals. Higher NPAR were significantly associated with increased risks of both all cause and CVD mortality. RCS analysis indicated J-shaped non-linear correlations between NPAR and both all-cause mortality and CVD mortality. Below threshold values (11.60 for all-cause and 12.29 for CVD mortality), increasing NPAR was associated with a decreased risk for both types of mortality. However, beyond these thresholds, elevated NPAR were found to correlate with increased mortality risks. Stratified analyses suggested the relationship between NPAR and mortality remained consistent across most subgroups, except for the race subgroup.
conclusionsNPAR were significantly associated with the risks of all-cause and CVD mortality in community-dwelling individuals with CKD. It suggested NPAR is a valuable tool for predicting the risk of mortality in CKD individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.